Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Refractory Chronic Lymphocytic Leukemia (CLL) Assessment Therapeutics Pipeline Review H1 2015 PowerPoint Presentation
Download Presentation
Refractory Chronic Lymphocytic Leukemia (CLL) Assessment Therapeutics Pipeline Review H1 2015

Refractory Chronic Lymphocytic Leukemia (CLL) Assessment Therapeutics Pipeline Review H1 2015

309 Views Download Presentation
Download Presentation

Refractory Chronic Lymphocytic Leukemia (CLL) Assessment Therapeutics Pipeline Review H1 2015

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Refractory Chronic Lymphocytic Leukemia- Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 24-Jun-2015 No. of pages: 249 Single User License: US $2000 Browse more Reports on Cancer Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Refractory Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 This report gives exhaustive data on the restorative improvement for Refractory Chronic Lymphocytic Leukemia (CLL), complete with near investigation at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and particle sort, alongside most recent upgrades, and included news and press discharges. It likewise audits key players included in the restorative advancement for Refractory Chronic Lymphocytic Leukemia (CLL) and unique components on late-stage and suspended undertakings. The report upgrades choice making capacities and help to make successful counter methods to increase upper hand. It reinforces R&D pipelines by distinguishing new targets and MOAs to deliver first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Refractory Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research: 4SC AG,AbbVie Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, BoehringerIngelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cellular Biomedicine Group, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, ImmunoGen, Inc and more Drugs Profile Discussed in this Research : 4SC-202, ACP-196, afuresertib hydrochloride, AGS-67E, AT-7519, AZD-6738, BI-836826, BMS-986016, buparlisib hydrochloride, CBM-C19.1, CBM-C20.1, CC-122, Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia, cerdulatinib, duvelisib, evofosfamide, FBTA-05, GS-9901, IMGN-529, IMMU-114, IPH-2201, and more ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Refractory Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 Scope For This Research: • The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Refractory Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Refractory Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441